


# Infection Control Hospital Epidemiology


Volume 36 No 6





## **Maximize CHG effectiveness**

with the only no-rinse prep cloth



2% Chlorhexidine Gluconate Cloth

features a leave-on antiseptic that significantly reduces the number of microorganisms on the skin to lower the risk of surgical site infection (SSI). It's easy to use and more effective than 4% CHG rinse-off options.1

A recent study found a 72% reduction in SSI and a \$2.97 million in annual savings by implementing 2% Chlorhexidine Gluconate Cloths for early prepping.2



Move beyond the shower in your SSI risk reduction approach to early prepping.





Enhance your SSI prevention efforts with the no-rinse 2% Chlorhexidine Gluconate Cloth. Call 800.323.2220 or visit www.sageproducts.com/chg today!

References: 1. Edmiston CE, et al., Comparative of a new and Innovative 2% chlorhexidine gluconate-impregnated cloth with 4% chlorhexidine gluconate as topical antiseptic for preparation of the skin prior to surgery. American Journal of Infection Control (AJIC), Mar 2007;35(2):89-96, 2. Kapadia BH, et al., Economic Evaluation of Chlorhexidine Cloths on Healthcare Costs due to Surgical Site Infections Following Total Knee Arthroplasty, J Arthroplasty (2013).



Volume 36 2015 Number 6

#### **CONTENTS**

#### Commentary

623 Challenges in Managing Patients who have Suspected or Confirmed Ebola Virus Infection at the National Institutes of Health

Tara N. Palmore, Kevin Barrett, Angela Michelin, Amanda Ramsburg, Laura M. Lee, Richard T. Davey, Jr. and David K. Henderson

#### **Original Articles**

- 627 Lessons Learned From Hospital Ebola Preparation
  Daniel J. Morgan, Barbara Braun, Aaron M. Milstone, Deverick Anderson, Ebbing Lautenbach,
  Nasia Safdar, Marci Drees, Jennifer Meddings, Darren R. Linkin, Lindsay D. Croft, Lisa Pineles,
  Daniel J. Diekema and Anthony D. Harris
- 632 Commentary: Ebola as a Test for Emerging Pathogen Preparedness: The Critical Role of Health Systems in Ensuring Support

  Mohamad G. Fakih. Michelle Heavens and Ann Hendrich
- 634 Endoscopic Retrograde Cholangiopancreatography—Associated AmpC Escherichia coli Outbreak Kristen A. Wendorf, Meagan Kay, Christopher Baliga, Scott J. Weissman, Michael Gluck, Punam Verma, Marisa D'Angeli, Jennifer Swoveland, Mi-Gyeong Kang, Kaye Eckmann, Andrew S. Ross and Jeffrey Duchin
- 643 Commentary: ERCP Scopes: What Can We Do to Prevent Infections? William A. Rutala and David J. Weber
- 649 Impact of Medicare's Hospital-Acquired Condition Policy on Infections in Safety Net and Non-Safety Net Hospitals

  Louise Elaine Vaz, Kenneth P. Kleinman, Alison Tse Kawai, Robert Jin, William J. Kassler, Patricia S. Grant,

Melisa D. Rett, Donald A. Goldmann, Michael S. Calderwood, Stephen B. Soumerai and Grace M. Lee

- 656 Commentary: Decreasing Trends of Healthcare-Associated Infections: Multifactorial Synergy JaHyun Kang, Kenneth J. Smith and Cindy L. Bryce
- 658 The Perennial Problem of Variability In Adenosine Triphosphate (ATP) Tests for Hygiene Monitoring Within Healthcare Settings

  Greg S. Whiteley, Chris Derry, Trevor Glasbey and Paul Fahey
- 664 Long-Term Outcomes of an Antimicrobial Stewardship Program Implemented in a Hospital with Low Baseline Antibiotic Use
  - Timothy C. Jenkins, Bryan C. Knepper, Katherine Shihadeh, Michelle K. Haas, Allison L. Sabel, Andrew W. Steele, Michael L. Wilson, Connie S. Price, William J. Burman and Philip S. Mehler
- 673 Clinical Diagnoses and Antimicrobials Predictive of Pediatric Antimicrobial Stewardship Recommendations: A Program Evaluation
  - Jennifer L. Goldman, Brian R. Lee, Adam L. Hersh, Diana Yu, Leslie M. Stach, Angela L. Myers, Mary Anne Jackson, James C. Day, Russell J. McCulloh and Jason G. Newland
- 681 The Cost–Benefit of Federal Investment in Preventing *Clostridium difficile* Infections through the Use of a Multifaceted Infection Control and Antimicrobial Stewardship Program *Rachel B. Slayton, R. Douglas Scott II, James Baggs, Fernanda C. Lessa, L. Clifford McDonald and John A. Jernigan*

- 688 Assessment of Antimicrobial Utilization Metrics: Days of Therapy Versus Defined Daily Doses and Pharmacy Dispensing Records Versus Nursing Administration Data Bruce R. Dalton, Deana M. Sabuda, Lauren C. Bresee and John M. Conly
- 695 Predicting the Risk for Hospital-Onset *Clostridium difficile* Infection (HO-CDI) at the Time of Inpatient Admission: HO-CDI Risk Score *Ying P. Tabak, Richard S. Johannes, Xiaowu Sun, Carlos M. Nunez, and L. Clifford McDonald*
- **702** Strict Infection Control Leads to Low Incidence of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection over 20 Years *Andreas F. Widmer, Botond Lakatos and Reno Frei*
- 710 Denominator Doesn't Matter: Standardizing Healthcare-Associated Infection Rates by Bed Days or Device Days *Molly J. Horstman, Yu-Fang Li, Peter L. Almenoff, Ron W. Freyberg and Barbara W. Trautner*
- 717 Carrots and Sticks: Achieving High Healthcare Personnel Influenza Vaccination Rates without a Mandate Marci Drees, Kathleen Wroten, Mary Smedley, Tabe Mase and J. Sanford Schwartz

#### Review Article

725 Improving Outpatient Antibiotic Prescribing for Respiratory Tract Infections: Results of New Algorithms Used in European Trials

\*Robert Gaynes and Stuart Levy\*

#### **Concise Communications**

- 730 Characteristics of Bacteremia in Pediatric Oncology Patients Based on Pathogen Classification as Associated with the Gastrointestinal Mucosa or Skin *Aron Flagg, Sarah Worley and Charles B. Foster*
- 734 Effect of Chlorhexidine Bathing and Other Infection Control Practices on the Benefits of Universal Glove and Gown (BUGG) Trial: A Subgroup Analysis

  Daniel J. Morgan, Lisa Pineles, Michelle Shardell, Carol Sulis, Daniel H. Kett, Jason Bowling,

  Beverly M. Belton, Anthony D. Harris and the BUGG Study Primary Investigators
- 738 Identification of Methicillin-Susceptible or Methicillin-Resistant *Staphylococcus aureus* Carrier Status Preoperatively Using Polymerase Chain Reaction in Patients Undergoing Elective Surgery With Hardware Implantation
  - Serge P. Bebko, Patricia Byers, David M. Green and Samir S. Awad
- 742 Cold-Air Atmospheric Pressure Plasma Against *Clostridium difficile* Spores: A Potential Alternative for the Decontamination of Hospital Inanimate Surfaces *Tânia Claro, Orla J. Cahill, Niall O'Connor, Stephen Daniels and Hilary Humphreys*

#### Letter to the Editor

745 Adopting a Global Safety Standard for the Prevention of Ebola Needle Stick Exposures

Gabriella De Carli, Francesco M. Fusco, Vincenzo Puro, Giuseppe Ippolito and the EuroNHID

Working Group

An Official Publication of the Society for Healthcare Epidemiology of America

#### EDITOR

Suzanne F. Bradley, MD • Ann Arbor, MI

#### **DEPUTY EDITOR**

Carol A. Kauffman, MD • Ann Arbor, MI

#### SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD • Galveston, TX Gina Pugliese, RN, MS • Chicago, IL William Schaffner, MD • Nashville, TN

#### ASSOCIATE EDITORS

Carol Chenoweth, MD • Ann Arbor, MI Ebbing Lautenbach, MD, MPH • Philadelphia, PA David Weber, MD, MPH • Chapel Hill, NC

#### STATISTICS CONSULTANTS

Jon P. Furuno, PhD • Portland, OR Jessina C. McGregor, PhD • Portland, OR

### SECTION EDITOR FOR GUIDELINES, POSITION PAPERS, AND INVITED REVIEWS

Eli Perencevich, MD, MS • Iowa City, IA

#### MANAGING EDITOR

Meighan Schreiber, MSSA • New York, NY

#### PAST EDITORS

Infection Control
Richard P. Wenzel, MD, 1980-1987 (vols. 1-8)
Infection Control & Hospital Epidemiology
Richard P. Wenzel, MD, 1988-1992
(vols. 9-13)
Michael D. Decker, MD, 1993-2001 (vols. 14-22)
Barry M. Farr, MD, 2002-2004 (vols. 23-25)
William R. Jarvis, MD, 2005-2006 (vols. 26 and 27)

#### EDITORIAL ADVISORY BOARD

Deverick Anderson, MD, MPH • Durham, NC Anucha Apisarnthanarak, MD • Pratumthani, Thailand Lennox Archibald, MD, FRCP • Alachua, FL Hilary Babcock, MD • St. Louis, MO Shailen Banerjee, PhD • Atlanta, GA Elise M. Beltrami, MD, MPH • Atlanta, GA Jo Anne Bennett, RN, PhD • New York, NY David Birnbaum, PhD, MPH • Sidney, BC Marc Bonten, MD • Utrecht, Netherlands Christian Brun-Buisson, MD • Creteil, France John P. Burke, MD • Salt Lake City, UT David P. Calfee, MD, MS • New York, NY Yehuda Carmeli, MD, MPH • Tel Aviv, Israel Donald E. Craven, MD • Burlington, MA Christopher Crnich, MD, MS • Madison, WI Erika D'Agata, MD, MPH • Boston, MA Daniel Diekema, MD • Iowa City, IA Erik Dubberke, MD, MSPH • St. Louis, MO Charles E. Edmiston, Jr., PhD • Milwaukee, WI Theodore C. Eickhoff, MD • Denver, CO Mohamad Fakih, MD, MPH • Grosse Pointe Woods, MI Petra Gastmeier, MD • Berlin, Germany Jeffrey Gerber, MD, PhD • Philadelphia, PA Dale N. Gerding, MD • Hines, IL Donald A. Goldmann, MD . Boston, MA Nicholas Graves, PhD • Brisbane, Australia Donna Haiduven, RN, PhD, CIC • Tampa, FL Anthony D. Harris, MD, MPH • Baltimore, MD Elizabeth Henderson, PhD • Calgary, AB David K. Henderson, MD • Bethesda, MD Loreen A. Herwaldt, MD • Iowa City, IA

Peter N. R. Heseltine, MD • Brea, CA John A. Jernigan, MD, MS • Atlanta, GA James T. Lee, MD, PhD • St. Paul, MN L. Clifford McDonald, MD • Atlanta, GA Allison McGeer, MD • Toronto, ON Leonard A. Mermel, DO, ScM • Providence, RI Robert R. Muder, MD • Pittsburgh, PA Linda Mundy, MD • Collegeville, PA Joseph M. Mylotte, MD, CIC • Buffalo, NY Jan Evans Patterson, MD • San Antonio, TX David A. Pegues, MD • Philadelphia, PA Didier Pittet, MD, MS . Geneva, Switzerland Isaam Raad, MD • Houston, TX Manfred L. Rotter, MD, DipBact • Vienna, Austria William A. Rutala, PhD, MPH • Chapel Hill, NC Lisa Saiman, MD, MPH • New York, NY Sanjay Saint, MD, MPH • Ann Arbor, MI Sorana Segal-Maurer, MD • Flushing, NY Lynne M. Sehulster, PhD • Atlanta, GA John A. Sellick, DO • Amherst, NY Kent Sepkowitz, MD • New York, NY Andrew E. Simor, MD • Toronto, ON Philip W. Smith, MD • Omaha, NE Kurt Stevenson, MD, MPH • Columbus, OH Nimalie Stone, MD • Atlanta, GA Thomas Talbot, MD, MPH • Nashville, TN Paul Tambyah, MBBS • Singapore William Trick, MD • Chicago, IL Antoni Trilla, MD, PhD • Barcelona, Spain Robert A. Weinstein, MD • Chicago, IL Andreas Widmer, MD, MS . Basel, Switzerland Marcus Zervos, MD • Detroit, MI

Infection Control & Hospital Epidemiology (ISSN 0899-823X) is published monthly by Cambridge University Press, 32 Avenue of the Americas, New York, NY 10013, USA.

#### **Editorial Office**

Communications should be addressed to the Editor, *Infection Control & Hospital Epidemiology*, 32 Avenue of the Americas, New York, NY 10013 (email: mschreiber@cambridge.org; telephone: 212-337-5954, fax: 212-337-5959). Contributors should consult the Instructions for Contributors, which is available at the journal's Web site.

#### Advertising

Please direct advertising inquiries to M. J. Mrvica Associates, 2 West Taunton Avenue, Berlin, NJ 08009 (e-mail: mjmrvica@mrvica.com; telephone: 856-768-9360, fax: 856-753-0064). Publication of an advertisement in *Infection Control & Hospital Epidemiology* does not imply endorsement of its claims by the Society for Healthcare Epidemiology of America, by the Editor, or by Cambridge University Press.

#### **Permissions**

Articles may be copied or otherwise reused without permission only to the extent permitted by Sections 107 and 108 of the US Copyright Law. Permission to copy articles for personal, internal, classroom, or library use may be obtained from the Copyright Clearance Center (http://www.copyright.com, email: info@copyright.com). For all other uses, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale, please contact Cambridge University Press. Full details may be found at: www.cambridge.org/about-us/rights-permissions.


#### Subscriptions

The individual subscription rate for 2015 is \$224. Individuals have the option to order directly from Cambridge University Press. Institutional print + electronic and e-only subscriptions are available from Cambridge University Press and include unlimited online access; rates are tiered according to an institution's type and research output and may be reviewed at the journal's CJO homepage: http://journals.cambridge.org/ICE.

Please direct subscription inquiries and requests for back issues to Customer Services at Cambridge University Press, e-mail: subscriptions\_newyork@cambridge.org (USA, Canada, and Mexico) or journals@cambridge.org (outside of USA, Canada, and Mexico).

Postmaster: Send address changes to *Infection Control & Hospital Epidemiology*, Cambridge University Press, 100 Brook Hill Drive, West Nyack, NY 10994-2133, USA.

#### About the cover:



Starting in 2015, the cover format of each volume of Infection Control & Hospital Epidemiology will highlight one of the many professionals throughout history who not only recognized how disease might be spread, but also how epidemiological principles could be applied to reduce healthcare associated infections.

Ignaz Semmelweiss (1818-1865) was a Hungarian physician who was appointed an assistant in obstetrics at the Allgemeines Krankenhaus in Vienna. He recognized that women delivered by midwife trainees were significantly less likely to die of puerperal fever than those delivered by physicians or medical students. He hypothesized that puerperal fever could be spread to mothers at the time of delivery by the hands of obstetricians that became contaminated while performing autopsies on women who had died in the maternity ward. Controlled trials of hand washing with chloride of lime solution and disinfection of instruments showed that he could reduce infections among the women cared for by physicians by almost 20-fold. Unfortunately, he did not publish his findings which contributed to the lack of acceptance of antisepsis among senior staff;

Semmelweiss' academic appointment was not renewed. He left for Budapest, but his beliefs failed to gain traction among colleagues in Hungary. Semmelweiss' increasingly erratic and angry behavior led to commitment to an asylum; he died there within a few short weeks at the age of 47 years. Contrary to legend, Semmelweiss' autopsy suggests that he did not die of streptococcal gangrene, but rather of trauma related to beatings inflicted by the guards at the asylum and an early Alzheimer-type dementia.





\* "Evaluation of a Pulsed Xenon Ultraviolet Disinfection System for Reduction of Healthcare-Associate Pathogens in Hospital Rooms," Infection Control & Hospital Epidemiology, Nerandzic, et. al, 2015 Tru-D is more effective than pulsed xenon's 5 minute claim.

Every high-touch surface in the room requires disinfection. Tru-D performs at 99.9% efficiency guaranteeing disinfection of all surfaces including shadowed areas within any room from a single placement.



**I** made a change that reduced HAIs in my hospital.

Sue Moeslein RN, MSA, CIC Riverside Regional Medical Center

#### Join Sue - Become a Face of Change Today.

CDC statistics show that in the United States, 1 in every 25 patients will contract a hospital acquired infection (HAI) costing upwards of \$30 billion annually, with close to 75,000 patients dying.

Our mission at Xenex is to eliminate the pathogens that cause infections affecting the health and lives of millions of patients and their families by providing the only Full Spectrum™ Pulsed Xenon UV Disinfection Robot.

#### Peer reviewed patient outcomes:

- ✓ 53% reduction in C. diff infection rates.¹
- ✓ 57% reduction in MRSA infection rates.<sup>2</sup>
- ✓ 100% elimination of VRE in isolation rooms.<sup>3</sup>

1. Levin J, et al., Cooley Dickinson in AJIC 2013, 41:746-748. 2. Simmons S et al., Cone Health System in JIP 2013. 3. Stibich M, et al., M.D. Anderson Cancer Center in ICHE 2011, 32:286-288.

